Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8513211 | 1.00 | MRGPRX1 (0.43) | MRGPRX1S1PR1HDAC1HDAC2SIGMAR1 | |
| SCHEMBL8512034 | 0.97 | S1PR1 (0.44) | MRGPRX1S1PR1HDAC1HDAC2SIGMAR1 | |
| SCHEMBL8512029 | 0.97 | S1PR1 (0.44) | MRGPRX1S1PR1HDAC1HDAC2SIGMAR1 | |
| SCHEMBL8510924 | 0.96 | S1PR1 (0.45) | MRGPRX1S1PR1HDAC1HDAC2SIGMAR1 | |
| SCHEMBL8510917 | 0.96 | S1PR1 (0.45) | MRGPRX1S1PR1HDAC1HDAC2SIGMAR1 | |
| SCHEMBL8512598 | 0.92 | S1PR1 (0.45) | MRGPRX1S1PR1HDAC1HDAC2SIGMAR1 | |
| SCHEMBL8512600 | 0.92 | S1PR1 (0.45) | MRGPRX1S1PR1HDAC1HDAC2SIGMAR1 | |
| SCHEMBL8513823 | 0.92 | S1PR1 (0.48) | MRGPRX1S1PR1HDAC1HDAC2SIGMAR1 | |
| SCHEMBL8513830 | 0.92 | S1PR1 (0.48) | MRGPRX1S1PR1HDAC1HDAC2SIGMAR1 | |
| SCHEMBL8513772 | 0.91 | S1PR1 (0.39) | MRGPRX1S1PR1HDAC1HDAC2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309768-B2 | FTY720-derived anticancer agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120136063-A1 | FTY720-DERIVED ANTICANCER AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136063-A1 | FTY720-DERIVED ANTICANCER AGENTS | SPHK2, S1PR2, S1PR1 | MRGPRX1 239/4885S1PR1 3/4885HDAC1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.